Fig. 6: Ly6d inhibition prevents hepatic steatosis in HFD-fed mice.
From: LY6D is crucial for lipid accumulation and inflammation in nonalcoholic fatty liver disease
Mice were intravenously injected with AAV-scrambled shRNA (control) or AAV-shLy6d (Ly6d-KD) (n = 5 in each group). Control-SCD: SCD-fed control mice; Control-HFD: HFD-fed control mice; Ly6d KD-SCD: SCD-fed Ly6d KD mice; Ly6d-HFD: HFD-fed Ly6d KD mice. A Western blot analysis of the relative Ly6d protein levels in liver tissues. B Body weight changes in mice from 8 weeks to 24 weeks. C Images of H&E and Picrosirius Red staining of livers from control and Ly6d KD mice. D qRT‒PCR analysis of the mRNA expression levels of genes related to lipid metabolism in HFD-fed control (orange) and HFD-fed Ly6d KD (light blue) mice. E Western blot analysis of proteins related to lipogenesis. F Heatmap-based visualization of the expression levels of genes related to NAFLD and NASH. SCD, standard chow diet; HFD, high-fat diet. The average value displayed in B and D is presented as the mean ± SED. The significance level for the relative expression indicated in D is *p < 0.05.
